[
  {
    "ts": null,
    "headline": "Merck Stock Jumps But Reddit Traders Are Getting Cold Feet",
    "summary": "A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week. The catalyst is Merck’s February 23 announcement to split its Human Health business into two divisions: one ... Merck Stock Jumps But Reddit Traders Are Getting Cold Feet",
    "url": "https://finnhub.io/api/news?id=6adedc0c8e3391fec1ba5621b0968fa86362d315cca8813b926b3a72096435b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772130307,
      "headline": "Merck Stock Jumps But Reddit Traders Are Getting Cold Feet",
      "id": 139238466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week. The catalyst is Merck’s February 23 announcement to split its Human Health business into two divisions: one ... Merck Stock Jumps But Reddit Traders Are Getting Cold Feet",
      "url": "https://finnhub.io/api/news?id=6adedc0c8e3391fec1ba5621b0968fa86362d315cca8813b926b3a72096435b0"
    }
  },
  {
    "ts": null,
    "headline": "This US Bancorp Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=856bd38e9756353b5c1ab292aa5994b083a3517663c2a6a39277c0e0ed69cc0e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772116649,
      "headline": "This US Bancorp Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday",
      "id": 139247582,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Richfield--Mn---usa---June-21--2014-Us-B_0.jpeg?width=2048&height=1536",
      "related": "MRK",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=856bd38e9756353b5c1ab292aa5994b083a3517663c2a6a39277c0e0ed69cc0e"
    }
  },
  {
    "ts": null,
    "headline": "Tenax Therapeutics: Some Future Potential",
    "summary": "Tenax Therapeutics: Some Future Potential",
    "url": "https://finnhub.io/api/news?id=81a3a7b9d05b74435cbea2450449681031a9c96a3d2c9ee6736a0ab24a480a70",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772114857,
      "headline": "Tenax Therapeutics: Some Future Potential",
      "id": 139238025,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=81a3a7b9d05b74435cbea2450449681031a9c96a3d2c9ee6736a0ab24a480a70"
    }
  },
  {
    "ts": null,
    "headline": "Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer",
    "summary": "MENLO PARK, Calif., February 26, 2026--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ong",
    "url": "https://finnhub.io/api/news?id=be3f256d278d6b31a9f774d97935bc67777a8fe3cf01c240bba6f453b8871d35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772110800,
      "headline": "Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer",
      "id": 139232180,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MENLO PARK, Calif., February 26, 2026--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed cell death receptor-1) therapy, in the ong",
      "url": "https://finnhub.io/api/news?id=be3f256d278d6b31a9f774d97935bc67777a8fe3cf01c240bba6f453b8871d35"
    }
  },
  {
    "ts": null,
    "headline": "For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.",
    "summary": "“Botox on steroids”: Old hair-loss drugs are getting an upgrade, and new ones are on the way.",
    "url": "https://finnhub.io/api/news?id=2195b4290cedda0943e9280b620373947a33d280d12c3916c5e175c50112abdb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772109540,
      "headline": "For the first time in decades, new hair-loss treatments are in the works. Here’s how they’re different.",
      "id": 139232181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "“Botox on steroids”: Old hair-loss drugs are getting an upgrade, and new ones are on the way.",
      "url": "https://finnhub.io/api/news?id=2195b4290cedda0943e9280b620373947a33d280d12c3916c5e175c50112abdb"
    }
  },
  {
    "ts": null,
    "headline": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
    "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
    "url": "https://finnhub.io/api/news?id=8eb35758f7955720bbbd2d670484763dbd968cc6c076ad5441589a2a5fabb5ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772105580,
      "headline": "Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030",
      "id": 139230952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing biomarker detection, and personalized therapies. Challenges include regulatory hurdles and standardization complexity. Key players include QIAGEN NV, Abbott, and Merck. Immunoassay for Neurological Biomarkers Market Immunoassay for Neurological Biomarkers Market Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The \"Immuno",
      "url": "https://finnhub.io/api/news?id=8eb35758f7955720bbbd2d670484763dbd968cc6c076ad5441589a2a5fabb5ac"
    }
  },
  {
    "ts": null,
    "headline": "This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=ee97229b03c82558c6b730e573cd68dc7fc880c2c23e1ce1f678c82082ce440b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772098683,
      "headline": "This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday",
      "id": 139231907,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Franklin---April-21--2024-Pfizer-Site-Ma.jpeg?width=2048&height=1536",
      "related": "MRK",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=ee97229b03c82558c6b730e573cd68dc7fc880c2c23e1ce1f678c82082ce440b"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
    "summary": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
    "url": "https://finnhub.io/api/news?id=09a87a4bea1335869f8b9bc61326a1312fc18461b27f445fd70bb784cf5e9447",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772091011,
      "headline": "Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie",
      "id": 139231313,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=09a87a4bea1335869f8b9bc61326a1312fc18461b27f445fd70bb784cf5e9447"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product […]",
    "url": "https://finnhub.io/api/news?id=d924bd47e8ef67c6b6329fe61f90b1a067af6a3a007f25f635aa72b49528e3d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772074082,
      "headline": "RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects",
      "id": 139227896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product […]",
      "url": "https://finnhub.io/api/news?id=d924bd47e8ef67c6b6329fe61f90b1a067af6a3a007f25f635aa72b49528e3d4"
    }
  }
]